HALO Halozyme Therapeutics, Inc. Final Profit

Corporate emblem and logo of Halozyme (HALO)

Risks for Halozyme Therapeutics (HALO) are linked to a dependence on partner success and their patent expiration dates. The company's aggregate net income on this chart reflects capital management dynamics, where 0.41 expresses the current value of the metric. The business relies on ENHANZE licensing, which guarantees high margins and a stable cash cow. A flawless brand image confirms the trust that pharmaceutical behemoths place in the effectiveness of their developments.

HALO (Halozyme Therapeutics) Net Profit history from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company Halozyme (HALO)

- stock value and consensus price forecast:
Market Price Halozyme Corp|HALO - Price Target Chart
- market capitalization data:
Market Value Halozyme Corp|HALO - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Halozyme|HALO - Book Capitalization|Market Cap to Net Assets Ratio halozyme.com|HALO - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Halozyme Therapeutics|HALO - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Halozyme Therapeutics, Inc.|HALO - Company Aggregate Debts|Debts to Book Value Halozyme Corp|HALO - Company Long-Term Debts|Company Short-Term Loans and Borrowings Halozyme|Quick Ratio halozyme.com
- net income and valuation multiples indicators:
HALO - Company Net Income
Fundamental valuation:HALO Halozyme Corp
Manufactured product of Halozyme Therapeutics, Inc.

The indicator is calculated as the final financial result after deducting all operating and tax expenses from total income. This metric compares market capitalization expectations with the actual volume of value generated. For Halozyme Therapeutics (HALO), high Big Pharma loyalty to its drug delivery platform ensures a steady inflow of capital. The fundamental reliability of the business is confirmed by the company's current profit level. The stability of this curve minimizes the risks of profit shortfalls.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Revolution Medicines|AAPG: Final Profit|Net Income CGON (CG Oncology)|URGN (UroGen Pharma Ltd) - Final Profit|Net Profit BCAX (Bicara Bio)|PSNL - Net Income|ERAS: Net Income|DCTH - Net Profit|Y-mAbs Therapeutics, Inc. (YMAB) - Company Net Income|Aura Biosciences Inc - Final Profit|CADL (Candel Therapeutics Inc.) - Net Profit|Company Net Income Accuray, Inc. ARAY|Net Profit SLS|ACTU (actuatetherapeutics.com) - Final Profit|Net Profit CTOR (Citius Oncology)|Net Profit TuHURA Biosciences Inc. HURA|TARA - Company Net Income|FATE: Company Net Income|aadibio.com (WHWK) - Company Net Income|Company Net Income TScan Therapeutics, Inc. (TCRX)|Net Income CSBR|XBiotech USA - Profit After Tax|Net Income CVM (CEL-SCI Corporation)|OSTX - Company Net Income|Company Net Income Radiopharm Theranostics Limited RADX|ARTV - Net Income|Adlai Nortye Limited - Net Profit|Company Net Income Veru Inc|TPST (Tempest Tx) - Net Income|Xilio Therapeutics - Final Profit|Net Income RENB|MURA (Mural Bio) - Profit After Payment of Taxes|Net Profit KAPA|OKUR (onkuretherapeutics.com) - Final Profit|Net Profit GDTC (CytoMed Therapeutics Limited)|Curis Inc. (CRIS) - Company Net Income|APLM - Company Net Income|Final Profit THAR (tharimmune.com)|ADVB: Net Profit|Genprex Inc. (GNPX) - Net Profit|Company Net Income Calidi Biotherapeutics Inc.|Sunshine Biopharma Inc. - Profit After Tax|Net Profit XBIO|SLRX - Company Net Income|Purple Biotech Ltd. - Net Income|Net Profit American Oncology Network Inc AONC|BGNE: Net Income|Checkpoint Therapeutics Inc - Profit After Payment of Taxes|ELEV: Net Profit|ICAD - Net Financial Result|IKNA (Ikena Oncology Inc.) - Net Profit|Net Income Notable Labs Ltd (NTBL)|Company Net Income Viracta Therapeutics (VIRX)|Net Financial Result MorphoSys Corporation|Net Profit NAYA (NAYA Biosciences)|Final Profit AAPGV